Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2

Fig. 3

Silence of AGR2 enhanced doxorubicin-sensitivity of MCF-7 cells in vivo. MCF-7 cells, stably transduced with a control shRNA vector or an AGR2-shRNA vector, were inoculated subcutaneously into BALB/c Nude mice at a dose of 5 × 106 per mouse (n = 4 in each group). Mice were injected intraperitoneally with PBS or doxorubicin (5 mg/kg) once on day 12, 15 and 18 after cell inoculation (indicated by arrows in panel A). a Tumor size was measured continuously. b-e On day 32, tumors were collected from mice followed by morphological (b) and histological analyses (c). d-e Immunohistochemistry was performed to detect expression of Ki-67 and cleaved caspase-3 in tumor tissues. TUNEL assay was applied to dectec apoptosis. Scale bar in (c and d): 500 μm. e Percent of Ki-67-positive cells, apoptotic cells and cleaved caspase-3-positive cells were counted. Experiment was repeated twice. Data are shown as mean ± SD, compared using one-way ANOVA test. *, p < 0.05; n.s., no significance; Doxo, doxorubicin

Back to article page